MS Spasticity and Medical Cannabis: Latest Research

New Research on Medical Cannabis for MS Spasticity

For patients with multiple sclerosis (MS), spasticity can be one of the most challenging symptoms to manage. Over the last few years, peer-reviewed research from PubMed has explored whether medical cannabis may help ease MS spasticity. While these studies suggest some potential benefits, it’s important to remember that medical cannabis may not work the same way for everyone. Always talk with your physician before starting any new treatment.

Nabiximols: Beyond Spasticity

A 2025 study in Medical Sciences reviewed research on nabiximols, a standardized cannabis extract approved as an add-on therapy for moderate to severe MS-related spasticity in some countries. The researchers also looked at whether nabiximols might help with other MS symptoms. While spasticity was the primary focus, the study suggested that nabiximols could have broader benefits in managing MS symptoms, though more research is needed to confirm these findings.

CBD’s Role in Neurological Conditions

Cannabidiol (CBD), a non-psychoactive compound in cannabis, has drawn significant attention for its potential therapeutic effects. A 2025 article in Pharmaceuticals highlighted CBD’s role in neurology, noting its anti-inflammatory and neuroprotective properties. While the study did not focus solely on MS, it suggested that CBD could be a promising area of research for managing neurological conditions, including neuroinflammation and pain. However, the authors emphasized the need for more clinical trials to fully understand CBD’s effects in MS patients.

Exploring Natural Compounds and Cannabinoid Receptors

Some research has looked at how natural compounds might interact with cannabinoid receptors in the body. A 2025 study in the American Journal of Clinical and Experimental Immunology used computational models to test whether compounds like berberine and curcumin could modulate cannabinoid receptor 1 (CB1), which plays a role in neuroprotection and inflammation. While this was a theoretical study—not a clinical trial—it suggested that these compounds could be worth further investigation for their potential in managing MS symptoms. However, real-world clinical studies would be needed to confirm these findings.

The Endocannabinoid System and Residual MS Symptoms

Even with high-efficacy therapies (HETs), some MS patients still experience symptoms like spasticity. A 2025 discussion in Frontiers in Neurology explored how enhancing the endocannabinoid system (ECS)—the body’s natural system that interacts with cannabis compounds—might help manage residual MS symptoms. The authors noted that the ECS plays a role in neuroprotection and inflammation, making it a potential target for future MS therapies. However, they stressed that more research is needed to determine how best to harness the ECS for symptom management.

Substance Use and Cognitive Function in MS

While many studies focus on the potential benefits of cannabis for MS, a 2025 study in Archives of Physical Medicine and Rehabilitation examined how psychoactive substances, including cannabis, might affect cognitive function in people with MS. The researchers used daily self-reports to track substance use and cognitive performance over two weeks. They found that cannabis use was not associated with significant changes in cognitive function in this small sample. However, the study was observational, meaning it could not establish cause and effect, and more research is needed to understand how cannabis affects cognition in MS patients.

Neuroprotective Effects of Cannabinoid Receptors

A 2025 study in Molecular Neurobiology investigated how cannabinoid receptors CB1 and GPR55 might protect against neurodegeneration in a cell model of MS. The researchers found that activating these receptors helped reduce cell damage, suggesting a potential neuroprotective role. While this study was conducted in cells—not in humans—it provides a foundation for future research into how cannabis compounds might help slow MS progression.

What Does This Mean for MS Patients?

The research on medical cannabis and MS spasticity is evolving, and while some studies suggest potential benefits, there is still much to learn. Medical cannabis may help some patients manage spasticity, but it may not work the same way for everyone. Side effects, interactions with other medications, and individual responses all play a role in whether cannabis is a suitable option.

If you’re considering medical cannabis for MS spasticity, the most important step is to talk with your physician. They can help you weigh the potential benefits and risks, discuss dosage and delivery methods, and ensure cannabis fits safely into your treatment plan.

At Compassionate Alternative Care, we’re here to support you with accurate, compassionate information about medical cannabis. To learn more about Florida’s medical marijuana program or to schedule a consultation, contact us today.